Aberrant methylation of tumor suppressor genes (TSG) such as SOCS-1, SOCS-3, SHP-1, and PRG2 has been documented in a variety of cancers including hematological malignancies [3, 36–42], and is a plausible means by which cells can acquire therapy resistance. Here, PRG2 is linked to cancer.